Iver

Información principal

  • Denominación comercial:
  • Iver New´s Profarma
  • Usar para:
  • Animales
  • Tipo de medicina:
  • medicamento alopático

Documentos

Localización

  • Disponible en:
  • Iver New´s Profarma
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • última actualización:
  • 03-09-2018

Prospecto

New´s Profarma

FABRICANTE:Laboratorios Profarma

7-11-2018

Murray Wholesale Cash & Carry recalls King Universal Butane Fuel

Murray Wholesale Cash & Carry recalls King Universal Butane Fuel

The recalled products do not have proper hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

20-9-2018

Mictonorm®. Propiverina para la incontinencia urinaria: Otro anticolinérgico, sin más

FET Número 1, BIT Navarra 14 de septiembre de 2018 Eficacia y seguridad similares a tolterodina. Como otros fármacos de su grupo, sólo estaría indicado cuando las medidas no farmacológicas son insuficientes

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

10-7-2018

Ortovox Canada recalls Ortovox 3 Avalanche Transceivers

Ortovox Canada recalls Ortovox 3 Avalanche Transceivers

The recalled products may have a temporary disruption of the transmission function due to a software error. This may cause a delay in the search and rescue process of users.

Health Canada

9-6-2018

Comer carne procesada se asocia con un empeoramiento de la función física

Comer carne procesada se asocia con un empeoramiento de la función física

Expertos del departamento de Medicina Preventiva y Salud Pública de la Universidad Autónoma de Madrid (UAM) han encontrado que personas con una ingesta elevada de carnes procesadas tienen un 30 % más probabilidades de empeorar su función física, en comparación con otros individuos que apenas consumen este tipo de alimentos. Sin embargo, la toma elevada […]

Cuba - infomed - Red de Salud de Cuba

9-6-2018

La electroencefalografía como método de análisis de la percepción audiovisual

La electroencefalografía como método de análisis de la percepción audiovisual

Personal de investigación de la División de Neurociencias de la Universidad Pablo de Olavide de Sevilla (UPO) y del Departamento de Comunicación Audiovisual y Publicidad de la Universitat Autònoma de Barcelona (UAB) junto con el Instituto de Radio Televisión Española (IRTVE), han publicado un artículo en la Journal of Visualized Experiments (JoVE) en el que se […]

Cuba - infomed - Red de Salud de Cuba

9-6-2018

Nuevo método de control antidopaje con resultados precisos en solo un día

Nuevo método de control antidopaje con resultados precisos en solo un día

Científicos del grupo Química Analítica de la Universidad de Jaén (UJA) han desarrollado un nuevo método de control antidopaje más rápido, sencillo y fiable. Los resultados de los análisis alcanzan una mayor o similar precisión que los actuales y se obtienen en un día, lo que agiliza el proceso, que hasta ahora, requiere varias jornadas. […]

Cuba - infomed - Red de Salud de Cuba

7-6-2018

Probado con éxito en pacientes un tratamiento contra la mucositis

Probado con éxito en pacientes un tratamiento contra la mucositis

Un compuesto desarrollado por científicos de la Universidad de Granada (UGR) para la prevención y tratamiento de la mucositis oral en pacientes de cáncer de cabeza y cuello tratados con quimio y radioterapia ha finalizado con éxito el ensayo clínico en fase I/IIa. La mucositis oral es un efecto secundario de ambas terapias contra el […]

Cuba - infomed - Red de Salud de Cuba

6-6-2018

Un biorreactor para crear tejido humano artificial

Un biorreactor para crear tejido humano artificial

Los laboratorios de Evaluación no Destructiva (grupo de Ultrasonidos TEP959 y de Biomecánica TEC12) y el laboratorio de Medicina Regenerativa (grupo CTS-963: Diferenciación, Regeneración y Cáncer) de la Universidad de Granada han trabajado conjuntamente para desarrollar un biorreactor, un dispositivo capaz de hacer crecer tejidos humanos artificiales. Como novedad, incorpora unos transductores emisores y receptores […]

Cuba - infomed - Red de Salud de Cuba

5-6-2018

Camellia sinensis (green tea) extract

Camellia sinensis (green tea) extract

Safety advisory - potential risk of harm to the liver

Therapeutic Goods Administration - Australia

4-6-2018

Desarrollan compuestos para frenar el alcoholismo

Desarrollan compuestos para frenar el alcoholismo

El grupo de investigación de Farmacología de la Universidad CEU San Pablo de Gonzalo Herradón, en colaboración con el grupo de diseño y síntesis de fármacos de las profesoras de la Facultad de Farmacia de la misma Universidad, Beatriz de Pascual-Teresa y Ana Ramos, y con el grupo de la Dra. Amy Lasek de la […]

Cuba - infomed - Red de Salud de Cuba

21-5-2018

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure.

FDA - U.S. Food and Drug Administration

25-4-2018

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...

FDA - U.S. Food and Drug Administration

19-3-2018

Arthrem capsules

Arthrem capsules

Safety advisory – potential risk of harm to the liver

Therapeutic Goods Administration - Australia

15-3-2018

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

OTTAWA - Health Canada is advising Canadians that it will be conducting a safety review of Fibristal (ulipristal acetate), a medication used to treat uterine fibroids in women. Health Canada's review is a result of Canadian and European reports of serious adverse events affecting the liver.

Health Canada

15-2-2018

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

The Danish Medicines Agency recommends doctors not to start any new patients on the medicine Esmya (ulipristal) because of a rare, but possible, risk of developing serious liver injury.

Danish Medicines Agency

9-11-2011

Danish Pharmacovigilance Update, 20 October 2011

Danish Pharmacovigilance Update, 20 October 2011

In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.

Danish Medicines Agency

10-10-2018

Diversity in research means more treatments work for more people. Join #ResearchDiversity Day on October 23rd for a day-long discussion of diversity in study recruitment and research. Join us! @Alzheimers_NIHpic.twitter.com/AwYhetCBiw

Diversity in research means more treatments work for more people. Join #ResearchDiversity Day on October 23rd for a day-long discussion of diversity in study recruitment and research. Join us! @Alzheimers_NIHpic.twitter.com/AwYhetCBiw

Diversity in research means more treatments work for more people. Join #ResearchDiversity Day on October 23rd for a day-long discussion of diversity in study recruitment and research. Join us! @Alzheimers_NIH pic.twitter.com/AwYhetCBiw

FDA - U.S. Food and Drug Administration

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency

29-6-2018

EU/3/18/2029 (Klinikum der UniversitAt MUnchen)

EU/3/18/2029 (Klinikum der UniversitAt MUnchen)

EU/3/18/2029 (Active substance: 2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one) - Orphan designation - Commission Decision (2018)4174 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/004/18

Europe -DG Health and Food Safety

11-6-2018

.@CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more:  http://go.cms.gov/1jc4cdC 

.@CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more: http://go.cms.gov/1jc4cdC 

. @CMSGov is issuing guidance today to make sure patients who use Continuous Glucose Monitors (CGMs) to help control their #diabetes can use apps on their smartphones in conjunction with CGM receivers. Learn more: http://go.cms.gov/1jc4cdC 

FDA - U.S. Food and Drug Administration